Table 1.
Disease | Target antigen | Routine multi-step approach1 |
---|---|---|
Pemphigus vulgaris |
Desmoglein 3 |
Desmoglein 3 ELISA[22] |
Pemphigus foliaceus |
Desmoglein 1 |
Desmoglein 1 ELISA[22] |
Paraneoplastic pemphigus |
Desmoglein 3 |
Desmoglein 3 ELISA[22] |
Envoplakin |
Envoplakin ELISA[21] |
|
Periplakin/ Desmoplakin I/II |
Immunoblot with extract of cultured HaCaT cells
[21] |
|
Indirect IF microscopy on rat and monkey bladder | ||
Bullous pemphigoid |
BP180 |
BP180 NC16A ELISA[20] |
BP230 |
BP230 ELISA[51] |
|
Soluble ectodomain of BP180 (LAD-1) |
BP180 4575 (c-terminal fragment) Immunoblot
[33,63] |
|
LAD-1 Immunoblot
[33,63] | ||
Pemphigoid gestationis |
BP180 |
BP180 NC16A ELISA[20] |
Complement binding test | ||
Linear IgA dermatosis |
Soluble ectodomain of BP180 (LAD-1) |
Immunoblot with conditioned medium of cultured HaCaT cells (IgA reactivity) )
[33,63] |
BP230 |
BP230 ELISA[51] |
|
Lichen planus pemphigoides |
BP180 |
BP180 NC16A ELISA[51] |
BP230 |
BP230 ELISA[51] |
|
Mucous membrane pemphigoid |
Soluble ectodomain of BP180 (LAD-1) |
Immunoblot with conditioned medium of cultured HaCaT cells (IgG and IgA reactivity)
[33] |
BP180 |
BP180 NC16A ELISA
[20] |
|
BP230 |
BP230 ELISA
[51] |
|
Laminin 332 |
Immunoblot with extracellular matrix of cultured HaCaT cells
[13,35] |
|
laminin γ1/anti-p200 pemphigoid |
p200 protein/ Laminin γ1 |
Immunoblot with extract of human dermis
[34] |
Immunoblot with recombinant laminin γ1 C-term
[37] | ||
Epidermolysis bullosa acquisita |
Type VII collagen |
Immunoblot with recombinant NC1-domain of type VII collagen
[36] |
Dermatitis herpetiformis | Epidermal/tissue transglutaminase, gliadin | Transglutaminase ELISA deamidated gliadin-analogous fusion peptide-specific ELISA [32] |
1in addition, all sera were subjected to indirect IF microscopy on human salt-split skin and monkey esophagus. The exact diagnostic algorithm applied in this study is detailed in [38].
IF, immunofluorescence; LAD-1, linear IgA dermatosis antigen 1(soluble ectodomain of BP180); BP180NC16A, targeted extracellular domain of BP180.